சுருக்கம்
Effects of thyroxine tablet combined with iodine supplementation and dietary therapy on serum Midkine and VEGF in patients with benign thyroid nodules
Jihua Zhang, Hualong Zhang, Meng Xu, Fan Zhang
Objective: To investigate the efficacy of thyroxine tablets combined with iodine supplementation and dietary therapy in the treatment of benign thyroid nodules and its effect on serum Midkine as well as Vascular Endothelial Growth Factor (VEGF).
Method: A total of 116 patients with benign thyroid nodules treated in our hospital were randomly divided into treatment group and control group with 58 cases in each group in which the control group were given thyroxine tablet treatment with non-iodized salt in daily diet while the treatment group were additionally given edible iodized salt and dietary intervention besides thyroxine treatment, the thyroid hormone level as well as serum Midkine and VEGF levels before and after the treatment and the incidence of adverse reactions were compared between the two groups.
Results: Before treatment, there was no statistically significant difference between the two groups in the levels of FT3, FT4 and TSH (P>0.05); while after treatment, levels of FT3, FT4 and TSH were improved in both groups compared with before with the improvement in the treatment group more significant than in the control group (P<0.05). Before treatment, there was no significant difference in serum Midkine and VEGF levels between the two groups (P>0.05) while after treatment, the levels of Midkine and VEGF in the treatment group were significantly lower than those in the control group (P<0.05). The total effective rate of the treatment group was 94.83%, higher than that of the control group, that was 84.48%, and the difference between the two groups was statistically significant (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05).
Conclusion: Compared with simple application of thyroxine tablet, thyroxine tablet combined with iodine supplement and dietary therapy is more effective in the treatment of benign thyroid nodules, which can effectively improve the level of thyroid hormone and reduce serum Midkine and VEGF levels with less adverse reactions, thus worthy of clinical promotion.